157 related articles for article (PubMed ID: 27913776)
1. Necitumumab for the treatment of squamous cell non-small cell lung cancer.
Brinkmeyer JK; Moore DC
J Oncol Pharm Pract; 2018 Jan; 24(1):37-41. PubMed ID: 27913776
[TBL] [Abstract][Full Text] [Related]
2. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Thatcher N; Hirsch FR; Luft AV; Szczesna A; Ciuleanu TE; Dediu M; Ramlau R; Galiulin RK; Bálint B; Losonczy G; Kazarnowicz A; Park K; Schumann C; Reck M; Depenbrock H; Nanda S; Kruljac-Letunic A; Kurek R; Paz-Ares L; Socinski MA;
Lancet Oncol; 2015 Jul; 16(7):763-74. PubMed ID: 26045340
[TBL] [Abstract][Full Text] [Related]
3. An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
Spigel DR; Luft A; Depenbrock H; Ramlau R; Khalil M; Kim JH; Mayo C; Chao GY; Obasaju C; Natale R
Clin Lung Cancer; 2017 Sep; 18(5):480-488. PubMed ID: 28365238
[TBL] [Abstract][Full Text] [Related]
4. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
Paz-Ares L; Mezger J; Ciuleanu TE; Fischer JR; von Pawel J; Provencio M; Kazarnowicz A; Losonczy G; de Castro G; Szczesna A; Crino L; Reck M; Ramlau R; Ulsperger E; Schumann C; Miziara JE; Lessa ÁE; Dediu M; Bálint B; Depenbrock H; Soldatenkova V; Kurek R; Hirsch FR; Thatcher N; Socinski MA;
Lancet Oncol; 2015 Mar; 16(3):328-37. PubMed ID: 25701171
[TBL] [Abstract][Full Text] [Related]
5. Necitumumab: First Global Approval.
Garnock-Jones KP
Drugs; 2016 Feb; 76(2):283-9. PubMed ID: 26729188
[TBL] [Abstract][Full Text] [Related]
6. Necitumumab: a new option for first-line treatment of squamous cell lung cancer.
Jiménez Aguilar E; Zugazagoitia Fraile J; Paz-Ares Rodríguez L
Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):765-772. PubMed ID: 30025476
[TBL] [Abstract][Full Text] [Related]
7. Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE).
Reck M; Thomas M; Kropf-Sanchen C; Mezger J; Socinski MA; Depenbrock H; Soldatenkova V; Brown J; Krause T; Thatcher N
Oncol Res Treat; 2016; 39(9):539-47. PubMed ID: 27614872
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
Ciuleanu T; Socinski MA; Obasaju C; Luft AV; Szczesna A; Szafrański W; Ramlau R; Bálint B; Molinier O; Depenbrock H; Nanda S; Paz-Ares L; Thatcher N
Clin Lung Cancer; 2018 Mar; 19(2):130-138.e2. PubMed ID: 29158123
[TBL] [Abstract][Full Text] [Related]
9. Necitumumab for the treatment of advanced non-small-cell lung cancer.
Díaz-Serrano A; Sánchez-Torre A; Paz-Ares L
Future Oncol; 2019 Mar; 15(7):705-716. PubMed ID: 30501503
[TBL] [Abstract][Full Text] [Related]
10. Necitumumab for non-small cell lung cancer.
Greillier L; Tomasini P; Barlesi F
Expert Opin Biol Ther; 2015; 15(8):1231-9. PubMed ID: 26051700
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update.
Pirker R
Curr Opin Oncol; 2015 Mar; 27(2):87-93. PubMed ID: 25636162
[TBL] [Abstract][Full Text] [Related]
12. Necitumumab in Metastatic Squamous Cell Lung Cancer: Establishing a Value-Based Cost.
Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; Ramalingam SS; Khuri FR; Flowers CR
JAMA Oncol; 2015 Dec; 1(9):1293-300. PubMed ID: 26313558
[TBL] [Abstract][Full Text] [Related]
13. Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer.
Losanno T; Rossi A; Maione P; Napolitano A; Gridelli C
Expert Opin Biol Ther; 2016 Jun; 16(6):747-58. PubMed ID: 26950292
[TBL] [Abstract][Full Text] [Related]
14. Association between skin toxicity and efficacy of necitumumab in squamous non-small-cell lung cancer: a pooled analysis of two randomized clinical trials-SQUIRE and JFCM.
Watanabe S; Yoshioka H; Sakai H; Hotta K; Takenoyama M; Yamada K; Sugawara S; Takiguchi Y; Hosomi Y; Tomii K; Niho S; Nishio M; Kato T; Takahashi T; Ebi H; Aono M; Yamamoto N; Ohe Y; Nakagawa K
ESMO Open; 2024 Apr; 9(4):102975. PubMed ID: 38520847
[TBL] [Abstract][Full Text] [Related]
15. Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer.
Sacco PC; Maione P; Rossi A; Sgambato A; Casaluce F; Palazzolo G; Gridelli C
Expert Rev Respir Med; 2015 Jun; 9(3):245-54. PubMed ID: 25797462
[TBL] [Abstract][Full Text] [Related]
16. Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies.
di Noia V; D'Argento E; Pilotto S; Grizzi G; Caccese M; Iacovelli R; Tortora G; Bria E
Expert Opin Biol Ther; 2018 Sep; 18(9):937-945. PubMed ID: 30075697
[TBL] [Abstract][Full Text] [Related]
17. Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development.
Dienstmann R; Felip E
Expert Opin Biol Ther; 2011 Sep; 11(9):1223-31. PubMed ID: 21679088
[TBL] [Abstract][Full Text] [Related]
18. Receptor kinase inhibitors target NSCLC: two antibodies and a small-molecule MET inhibitor.
Yee D
BioDrugs; 2011 Aug; 25(4):271-3. PubMed ID: 21815704
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies against EGFR in non-small cell lung cancer.
Pirker R; Filipits M
Crit Rev Oncol Hematol; 2011 Oct; 80(1):1-9. PubMed ID: 21109448
[TBL] [Abstract][Full Text] [Related]
20. Is there still room for large registrative trials in unselected cancer patients? The case of anti-epidermal growth factor receptor antibodies in advanced non-small-cell lung cancer.
Di Maio M
Expert Opin Biol Ther; 2011 Sep; 11(9):1131-3. PubMed ID: 21806477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
